Novel Immuno-oncology Combination Therapies for Renal Cell Carcinoma:

Evolving Considerations for Clinical Practice

Banner Image


Health Canada approves pembrolizumab as first-line treatment for patients with advanced renal cell carcinoma. BioSpace.com Web site. Available at: https://www.biospace.com/article/releases/health-canada-approves-keytruda-and-174-pembrolizumab-as-first-line-treatment-for-patients-with-advanced-renal-cell-carcinoma-rcc-/. Published January 23, 2020. Accessed February 3, 2020.

Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019; 30:706-720. Available at: https://www.annalsofoncology.org/article/S0923-7534(19)31157-3/fulltext.

Albiges L, Powles T, Staehler M, et al. Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition is the new backbone in first-line treatment of metastatic clear-cell renal cell carcinoma. Eur Urol. 2019;76:151-156. Available at: https://www.ncbi.nlm.nih.gov/pubmed/?term=10.1016%2Fj.eururo.2019.05.022.

Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019; 30:706-720. Available at: https://www.annalsofoncology.org/article/S0923-7534(19)31157-3/fulltext.

Albiges L, Powles T, Staehler M, et al. Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition is the new backbone in first-line treatment of metastatic clear-cell renal cell carcinoma. Eur Urol. 2019;76:151-156. Available at: https://www.ncbi.nlm.nih.gov/pubmed/?term=10.1016%2Fj.eururo.2019.05.022.

Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019; 30:706-720. Available at: https://www.annalsofoncology.org/article/S0923-7534(19)31157-3/fulltext.

Albiges L, Powles T, Staehler M, et al. Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition is the new backbone in first-line treatment of metastatic clear-cell renal cell carcinoma. Eur Urol. 2019;76:151-156. Available at: https://www.ncbi.nlm.nih.gov/pubmed/?term=10.1016%2Fj.eururo.2019.05.022. Accessed March 3, 2020.

Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019; 30:706-720. Available at: https://www.annalsofoncology.org/article/S0923-7534(19)31157-3/fulltext.

Albiges L, Powles T, Staehler M, et al. Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition is the new backbone in first-line treatment of metastatic clear-cell renal cell carcinoma. Eur Urol. 2019;76:151-156. Available at: https://www.ncbi.nlm.nih.gov/pubmed/?term=10.1016%2Fj.eururo.2019.05.022.

Lazaro M, Valderrama BP, Suarez C, et al. SEOM (Sociedad Espanola de Oncologia Medica) clinical guideline for treatment of kidney cancer (2019). Clin Transl Oncol. 2020;22:256-269. Available at: https://link.springer.com/content/pdf/10.1007/s12094-019-02285-7.pdf.

Uemura M, Tomita Y, Miyake H, et al. Avelumab plus axitinib vs sunitinib for advanced renal cell carcinoma: Japanese subgroup analysis from JAVELIN Renal 101. Cancer Sci. 2020;111:907-923. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7060483/.

Exelixis’ Partner Takeda Announces Filing of New Drug Application in Japan for Cabozantinib for Advanced Renal Cell Carcinoma. BioSpace.com Web site. Available at: https://www.biospace.com/article/releases/exelixis-partner-takeda-announces-filing-of-new-drug-application-in-japan-for-cabometyx-cabozantinib-for-advanced-renal-cell-carcinoma/. Published April 25, 2019. Accessed February 3, 2020.

Merck’s pembrolizumab approved in Japan for three new first-line indications across advanced renal cell carcinoma (RCC) and recurrent or distant metastatic head and neck cancer [press release]. Kenilworth, NJ: BusinessWire; December 20, 2019. Available at: https://www.businesswire.com/news/home/20191220005101/en/Merck%E2%80%99s-KEYTRUDA%C2%AE-pembrolizumab-Approved-Japan-New-First-Line.

Columbus G. Frontline pembrolizumab/axitinib approved in Japan for advanced RCC. OncLive.com Web site. Available at: https://www.onclive.com/web-exclusives/frontline-pembrolizumabaxitinib-approved-in-japan-for-advanced-rcc. Published December 20, 2019. Accessed February 3, 2020.